trial · primary record
Fitusiran
Hemophilia
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 85 |
| Primary completion | 2031-12-30 |
| Primary endpoint | Annualized treated bleeding rate (ABR) in the fitusiran primary efficacy period and in the SOC period |
| Registry ID | NCT07285460 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:50.069Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07285460
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.